Compare Torrent Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs WOCKHARDT - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA WOCKHARDT TORRENT PHARMA/
WOCKHARDT
 
P/E (TTM) x 56.5 -12.1 - View Chart
P/BV x 6.8 0.9 720.3% View Chart
Dividend Yield % 0.8 0.0 18,448.5%  

Financials

 TORRENT PHARMA   WOCKHARDT
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
WOCKHARDT
Mar-18
TORRENT PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,5501,012 153.2%   
Low Rs1,144532 215.1%   
Sales per share (Unadj.) Rs354.7355.9 99.7%  
Earnings per share (Unadj.) Rs40.1-60.3 -66.5%  
Cash flow per share (Unadj.) Rs64.2-46.8 -137.3%  
Dividends per share (Unadj.) Rs14.000.01 140,000.0%  
Dividend yield (eoy) %1.00 80,226.5%  
Book value per share (Unadj.) Rs273.1257.8 105.9%  
Shares outstanding (eoy) m169.22110.63 153.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.82.2 175.1%   
Avg P/E ratio x33.6-12.8 -262.5%  
P/CF ratio (eoy) x21.0-16.5 -127.1%  
Price / Book Value ratio x4.93.0 164.7%  
Dividend payout %34.90 -210,579.3%   
Avg Mkt Cap Rs m227,89785,379 266.9%   
No. of employees `00014.76.3 235.0%   
Total wages/salary Rs m11,3539,371 121.2%   
Avg. sales/employee Rs Th4,083.06,295.0 64.9%   
Avg. wages/employee Rs Th772.31,498.3 51.5%   
Avg. net profit/employee Rs Th461.3-1,066.3 -43.3%   
INCOME DATA
Net Sales Rs m60,02139,369 152.5%  
Other income Rs m2,9881,202 248.6%   
Total revenues Rs m63,00940,571 155.3%   
Gross profit Rs m13,49318 73,729.5%  
Depreciation Rs m4,0861,495 273.3%   
Interest Rs m3,0852,555 120.7%   
Profit before tax Rs m9,310-2,830 -329.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m2,529257 983.9%   
Profit after tax Rs m6,781-6,669 -101.7%  
Gross profit margin %22.50 48,360.9%  
Effective tax rate %27.2-9.1 -299.0%   
Net profit margin %11.3-16.9 -66.7%  
BALANCE SHEET DATA
Current assets Rs m52,62333,796 155.7%   
Current liabilities Rs m52,02226,917 193.3%   
Net working cap to sales %1.017.5 5.7%  
Current ratio x1.01.3 80.6%  
Inventory Days Days12079 150.7%  
Debtors Days Days7689 85.4%  
Net fixed assets Rs m85,01639,664 214.3%   
Share capital Rs m846553 153.0%   
"Free" reserves Rs m45,37627,968 162.2%   
Net worth Rs m46,22228,522 162.1%   
Long term debt Rs m41,11521,731 189.2%   
Total assets Rs m142,43281,620 174.5%  
Interest coverage x4.0-0.1 -3,737.1%   
Debt to equity ratio x0.90.8 116.7%  
Sales to assets ratio x0.40.5 87.4%   
Return on assets %6.9-5.0 -137.4%  
Return on equity %14.7-23.4 -62.8%  
Return on capital %14.2-7.7 -184.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5809,807 148.7%   
Fx outflow Rs m3,6001,789 201.3%   
Net fx Rs m10,9808,019 136.9%   
CASH FLOW
From Operations Rs m8,942684 1,306.5%  
From Investments Rs m-47,0706,302 -746.9%  
From Financial Activity Rs m34,174-7,695 -444.1%  
Net Cashflow Rs m-3,655-664 550.5%  

Share Holding

Indian Promoters % 71.5 74.5 96.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 2.3 305.2%  
FIIs % 12.6 7.7 163.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 8.8 15.4 57.1%  
Shareholders   26,511 67,757 39.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  FDC LTD.  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 6, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS